Semaglutide
Long-acting GLP-1 receptor agonist research compound with 94% homology to native GLP-1.
From · per box of 10 vials
$45
Triple agonist (GLP-1, GIP, glucagon) research compound for metabolic studies.
Retatrutide is a triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors — an advanced research compound for energy metabolism and body composition studies. For laboratory research use only.
Simultaneous activation of three receptors modulates glucose homeostasis, lipid oxidation, and appetite pathways.
Phase 2 metabolic trial data demonstrated significant weight reduction, making it a cutting-edge research reference.
For laboratory research only. Potent multi-receptor agonist; requires careful dosing in study designs.
From $100
per box of 10 vials
| Code | Dose | Price (USD) | Actions |
|---|---|---|---|
| RT5 | 5 mg | $100 | |
| RT10 | 10 mg | $160 | |
| RT15 | 15 mg | $220 | |
| RT20 | 20 mg | $265 | |
| RT30 | 30 mg | $325 | |
| RT40 | 40 mg | $385 | |
| RT50 | 50 mg | $420 | |
| RT60Only 2 left | 60 mg | $500 |
Research Use Only: All products are strictly intended for laboratory research and scientific analysis only. Not for human consumption, clinical use, or diagnostic applications.
Long-acting GLP-1 receptor agonist research compound with 94% homology to native GLP-1.
From · per box of 10 vials
$45
First-in-class dual GIP/GLP-1 receptor agonist for metabolic research.
From · per box of 10 vials
$55
Dual GLP-1/glucagon receptor agonist research compound.
From · per box of 10 vials
$355
Triple agonist (GLP-1, GIP, glucagon) research compound for metabolic studies — box of 10 vials.
From · per box of 10 vials
$180